Related Experiment Video

Updated: Jun 12, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice

Masatoshi Kudo1

  • 1Department of Gastroenterology and Hepatology, Kinki University School of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan. m-kudo@med.kindai.ac.jp

International Journal of Clinical Oncology
|May 29, 2010
PubMed

Insights

Sorafenib is the first molecular-targeted drug approved for liver cancer (HCC). Ongoing trials compare it with other agents targeting key pathways in HCC development and progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecular-targeted agents represent a significant advancement in treating malignant tumors.
  • Sorafenib (Nexavar) was the first molecular-targeted agent approved for unresectable hepatocellular carcinoma (HCC) in Japan in 2009.
  • Sorafenib is the sole molecular-targeted agent with demonstrated survival benefits in two global phase III trials, leading to worldwide approval.

Purpose of the Study:

  • To review the primary signaling pathways implicated in hepatocellular carcinoma (HCC) development and progression.
  • To discuss current and emerging molecular-targeted agents for HCC treatment.
  • To provide an overview of targeted therapies for liver cancer.

Main Methods:

  • Review of published literature on HCC signaling pathways.
  • Analysis of clinical trial data for molecular-targeted agents in HCC.
  • Summary of approved and investigational targeted therapies for liver cancer.

Main Results:

  • Sorafenib has established itself as a first-line treatment for HCC.
  • Multiple other molecular-targeted agents are under investigation in phase III trials.
  • These agents target key pathways including VEGFR, PDGFR, EGFR, IGF-1R, and mTOR.

Conclusions:

  • Molecular-targeted therapies have transformed HCC treatment paradigms.
  • Further research is exploring novel agents and combinations to improve patient outcomes.
  • Understanding HCC signaling pathways is crucial for developing effective targeted treatments.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...